Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center Experience.
10.3349/ymj.2012.53.5.944
- Author:
Tak Geun OH
1
;
Moon Jae CHUNG
;
Jeong Yeop PARK
;
Seung Min BANG
;
Seung Woo PARK
;
Jae Bok CHUNG
;
Si Young SONG
Author Information
1. Division of Gastroenterology, Department of Internal Medicine and Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. sysong@yuhs.ac
- Publication Type:Original Article
- Keywords:
Pancreatic neuroendocrine tumor;
prognostic factor;
liver metastasis;
bile duct invasion;
pancreatic duct invasion;
location of tumor
- MeSH:
Bile Ducts;
Disease Progression;
Disease-Free Survival;
Humans;
Joints;
Liver;
Lymph Nodes;
Methods;
Multivariate Analysis;
Neoplasm Metastasis;
Neuroectodermal Tumors, Primitive;
Neuroendocrine Tumors*;
Pancreas;
Pancreatic Ducts;
Prognosis;
Retrospective Studies;
Tail
- From:Yonsei Medical Journal
2012;53(5):944-951
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Pancreatic neuroendocrine tumors (PNET) are a rare subgroup of tumors. For PNETs, the predictive factors for survival and prognosis are not well known. The purpose of our study was to evaluate the predictive factors for survival and disease progression in PNETs. MATERIALS AND METHODS: We retrospectively analyzed 37 patients who were diagnosed with PNET at Severance Hospital between November 2005 and March 2010. Prognostic factors for survival and disease progression were evaluated using the Kaplan-Meier method. RESULTS: The mean age of the patients was 50.0+/-15.0 years. Eight cases (21.6%) were described as functioning tumors and 29 cases (78.4%) as non-functioning tumors. In univariate analysis of clinical factors, patients with liver metastasis (p=0.002), without resection of primary tumors (p=0.002), or American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) stage III/IV (p=0.002) were more likely to demonstrate shorter overall survival (OS). Patients with bile duct or pancreatic duct invasion (p=0.031), sized-lesions larger than 20 mm (p=0.036), liver metastasis (p=0.020), distant metastasis (p=0.005), lymph node metastasis (p=0.009) or without resection of primary tumors (p=0.020) were more likely to demonstrate shorter progression-free survival (PFS). In multivariate analysis of clinical factors, bile duct or pancreatic duct invasion [p=0.010, hazard ratio (HR)=95.046] and tumor location (non-head of pancreas) (p=0.036, HR=7.381) were confirmed as independent factors for predicting shorter PFS. CONCLUSION: Patients with liver metastasis or without resection of primary tumors were more likely to demonstrate shorter OS. Patients with bile duct or pancreatic duct invasion or tumors located at body or tail of pancreas were more likely to demonstrate shorter PFS.
